Literature DB >> 34662370

Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins.

Cristina Panaroni1, Keertik Fulzele1, Tomoaki Mori1, Ka Tat Siu1,2, Chukwuamaka Onyewadume1, Allison Maebius1, Noopur Raje1.   

Abstract

Adipocytes occupy 70% of the cellular volume within the bone marrow (BM) wherein multiple myeloma (MM) originates and resides. However, the nature of the interaction between MM cells and adipocytes remains unclear. Cancer-associated adipocytes support tumor cells through various mechanisms, including metabolic reprogramming of cancer cells. We hypothesized that metabolic interactions mediate the dependence of MM cells on BM adipocytes. Here we show that BM aspirates from precursor states of MM, including monoclonal gammopathy of undetermined significance and smoldering MM, exhibit significant upregulation of adipogenic commitment compared with healthy donors. In vitro coculture assays revealed an adipocyte-induced increase in MM cell proliferation in monoclonal gammopathy of undetermined significance/smoldering MM compared with newly diagnosed MM. Using murine MM cell/BM adipocyte coculture assays, we describe MM-induced lipolysis in adipocytes via activation of the lipolysis pathway. Upregulation of fatty acid transporters 1 and 4 on MM cells mediated the uptake of secreted free fatty acids (FFAs) by adjacent MM cells. The effect of FFAs on MM cells was dose dependent and revealed increased proliferation at lower concentrations vs induction of lipotoxicity at higher concentrations. Lipotoxicity occurred via the ferroptosis pathway. Exogenous treatment with arachidonic acid, a very-long-chain FFA, in a murine plasmacytoma model displayed a reduction in tumor burden. Taken together, our data reveal a novel pathway involving MM cell-induced lipolysis in BM adipocytes and suggest prevention of FFA uptake by MM cells as a potential target for myeloma therapeutics.
© 2022 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34662370      PMCID: PMC8832479          DOI: 10.1182/blood.2021013832

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  57 in total

1.  Megakaryocytes derived from embryonic stem cells implicate CalDAG-GEFI in integrin signaling.

Authors:  Koji Eto; Ronan Murphy; Steve W Kerrigan; Alessandra Bertoni; Heidi Stuhlmann; Toru Nakano; Andrew D Leavitt; Sanford J Shattil
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-18       Impact factor: 11.205

Review 2.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675

3.  Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells.

Authors:  J Caers; S Deleu; Z Belaid; H De Raeve; E Van Valckenborgh; E De Bruyne; M-P Defresne; I Van Riet; B Van Camp; K Vanderkerken
Journal:  Leukemia       Date:  2007-03-22       Impact factor: 11.528

4.  Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease.

Authors:  Huan Liu; Jin He; Su Pin Koh; Yuping Zhong; Zhiqiang Liu; Zhiqiang Wang; Yujin Zhang; Zongwei Li; Bjorn T Tam; Pei Lin; Min Xiao; Ken H Young; Behrang Amini; Michael W Starbuck; Hans C Lee; Nora M Navone; Richard E Davis; Qiang Tong; P Leif Bergsagel; Jian Hou; Qing Yi; Robert Z Orlowski; Robert F Gagel; Jing Yang
Journal:  Sci Transl Med       Date:  2019-05-29       Impact factor: 17.956

5.  Marrow adipocyte-derived CXCL1 and CXCL2 contribute to osteolysis in metastatic prostate cancer.

Authors:  Aimalie L Hardaway; Mackenzie K Herroon; Erandi Rajagurubandara; Izabela Podgorski
Journal:  Clin Exp Metastasis       Date:  2015-03-24       Impact factor: 5.150

6.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

Authors:  Robert A Kyle; Ellen D Remstein; Terry M Therneau; Angela Dispenzieri; Paul J Kurtin; Janice M Hodnefield; Dirk R Larson; Matthew F Plevak; Diane F Jelinek; Rafael Fonseca; Lee Joseph Melton; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

7.  Endomembrane PtdIns(3,4,5)P3 activates the PI3K-Akt pathway.

Authors:  Nirmal Jethwa; Gary H C Chung; Marta G Lete; Alicia Alonso; Richard D Byrne; Véronique Calleja; Banafshé Larijani
Journal:  J Cell Sci       Date:  2015-08-03       Impact factor: 5.285

8.  Bone marrow adipocytes promote the regeneration of stem cells and haematopoiesis by secreting SCF.

Authors:  Bo O Zhou; Hua Yu; Rui Yue; Zhiyu Zhao; Jonathan J Rios; Olaia Naveiras; Sean J Morrison
Journal:  Nat Cell Biol       Date:  2017-07-17       Impact factor: 28.824

9.  Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation.

Authors:  Zhiqiang Liu; Jingda Xu; Jin He; Huan Liu; Pei Lin; Xinhai Wan; Nora M Navone; Qiang Tong; Larry W Kwak; Robert Z Orlowski; Jing Yang
Journal:  Oncotarget       Date:  2015-10-27

Review 10.  Cancer-associated adipocytes: key players in breast cancer progression.

Authors:  Qi Wu; Bei Li; Zhiyu Li; Juanjuan Li; Si Sun; Shengrong Sun
Journal:  J Hematol Oncol       Date:  2019-09-10       Impact factor: 17.388

View more
  8 in total

Review 1.  The role of bone marrow adipocytes in cancer progression: the impact of obesity.

Authors:  Marine Hernandez; Sauyeun Shin; Catherine Muller; Camille Attané
Journal:  Cancer Metastasis Rev       Date:  2022-06-16       Impact factor: 9.237

Review 2.  Targeting Chemokine Receptor CCR1 as a Potential Therapeutic Approach for Multiple Myeloma.

Authors:  Annette Gilchrist; Stephanie L Echeverria
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-25       Impact factor: 5.555

Review 3.  Single-Cell Metabolomics in Hematopoiesis and Hematological Malignancies.

Authors:  Fengli Zuo; Jing Yu; Xiujing He
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738

4.  Calorie restriction has no effect on bone marrow tumour burden in a Vk*MYC transplant model of multiple myeloma.

Authors:  Vasilios Panagopoulos; Andrew C W Zannettino; Alanah L Bradey; Stephen Fitter; Jvaughn Duggan; Vicki Wilczek; Connor M D Williams; Emma Aj Cheney; Jacqueline E Noll; Pawanrat Tangseefa
Journal:  Sci Rep       Date:  2022-07-30       Impact factor: 4.996

Review 5.  Multiple myeloma metabolism - a treasure trove of therapeutic targets?

Authors:  Monica Roman-Trufero; Holger W Auner; Claire M Edwards
Journal:  Front Immunol       Date:  2022-08-22       Impact factor: 8.786

Review 6.  Reprogramming lipid metabolism as potential strategy for hematological malignancy therapy.

Authors:  Leqiang Zhang; Ning Chang; Jia Liu; Zhuojun Liu; Yajin Wu; Linlin Sui; Wei Chen
Journal:  Front Oncol       Date:  2022-08-29       Impact factor: 5.738

Review 7.  Targeting metabolic reprogramming in chronic lymphocytic leukemia.

Authors:  Yu Nie; Xiaoya Yun; Ya Zhang; Xin Wang
Journal:  Exp Hematol Oncol       Date:  2022-06-27

Review 8.  Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma.

Authors:  Inge Oudaert; Arne Van der Vreken; Anke Maes; Elke De Bruyne; Kim De Veirman; Karin Vanderkerken; Eline Menu
Journal:  Exp Hematol Oncol       Date:  2022-09-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.